Search

AB Science SA

Open

1.182 3.87

Overview

Share price change

24h

Current

Min

1.1179999999999999

Max

1.212

Key metrics

By Trading Economics

Income

-3.4M

Sales

512K

Profit margin

-656.641

Employees

36

EBITDA

-1.9M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+327.13% upside

Market Stats

By TradingEconomics

Market Cap

79M

Previous open

-2.69

Previous close

1.182

Technical Score

By Trading Central

Confidence

Bearish Evidence

AB Science SA Chart

Past performance is not a reliable indicator of future results.

Related News

30 Oct 2025, 23:32 UTC

Hot Stocks

Stocks to Watch: Amazon, Reddit, SPS Commerce

30 Oct 2025, 23:02 UTC

Earnings

AIA Group 3Q Value of New Business Grew

30 Oct 2025, 23:45 UTC

Market Talk

Gold Edges Higher Amid Prospects of Continued Central-Bank Demand -- Market Talk

30 Oct 2025, 23:00 UTC

Earnings

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 3rd Update

30 Oct 2025, 22:59 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

30 Oct 2025, 22:59 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Mineral Resources Bear Reckons Lithium Assets May Be Dressed Up For Sale -- Market Talk

30 Oct 2025, 22:56 UTC

Market Talk

Australia Shares Shaping to Pare Recent Losses -- Market Talk

30 Oct 2025, 22:35 UTC

Earnings

AIA Group 3Q Value of New Business Margin Was 58.2%, Up 5.7 Ppt on Year >1299.HK

30 Oct 2025, 22:35 UTC

Earnings

AIA Group 3Q Value of New Business $1.48B Vs. $1.16B>1299.HK

30 Oct 2025, 22:31 UTC

Earnings

Apple Expects Big December Quarter on iPhone Upgrades -- 2nd Update

30 Oct 2025, 22:29 UTC

Earnings

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 2nd Update

30 Oct 2025, 22:27 UTC

Earnings

Minas Buenaventura 3Q EPS 66c >BVN

30 Oct 2025, 22:27 UTC

Earnings

Minas Buenaventura 3Q Rev $431M >BVN

30 Oct 2025, 22:27 UTC

Earnings

Minas Buenaventura 3Q Net $179M >BVN

30 Oct 2025, 22:16 UTC

Market Talk
Earnings

Amazon's Grocery Delivery Business Gains Ground -- Market Talk

30 Oct 2025, 22:14 UTC

Earnings

Review & Preview: A Tech Earnings Storm -- Barrons.com

30 Oct 2025, 22:00 UTC

Earnings
Acquisitions, Mergers, Takeovers

The Day Pharma's Weight-Loss Gold Rush Intensified -- WSJ

30 Oct 2025, 21:39 UTC

Earnings

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

30 Oct 2025, 21:26 UTC

Earnings

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

30 Oct 2025, 21:14 UTC

Market Talk
Earnings

Apple Sees Record Quarterly Services Revenue -- Market Talk

30 Oct 2025, 21:09 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

30 Oct 2025, 21:09 UTC

Market Talk
Earnings

Amazon Says One-Off Costs Ate Into Operating Income -- Market Talk

30 Oct 2025, 21:04 UTC

Earnings

Apple Expects Big December Quarter on iPhone Upgrades -- Update

30 Oct 2025, 21:03 UTC

Earnings

Eldorado Gold 3Q Gold Sales Were 116,529 Ounces at Avg Realized Gold Price Per Ounce Sold of $3,527 >ELD.T

30 Oct 2025, 21:03 UTC

Earnings

Eldorado Gold 3Q Gold Production Was 115,190 Ounces >ELD.T

30 Oct 2025, 21:00 UTC

Earnings

Eldorado Gold Skouries on Track for 1Q of 2026

30 Oct 2025, 21:00 UTC

Earnings

Eldorado Gold 3Q Adj EPS 41c >EGO

30 Oct 2025, 21:00 UTC

Earnings

Eldorado Gold 3Q Rev $434.7M >EGO

30 Oct 2025, 21:00 UTC

Earnings

Eldorado Gold 3Q Net $56M >EGO

30 Oct 2025, 21:00 UTC

Earnings

Eldorado Gold 3Q EPS 27c >EGO

AB Science SA Forecast

Price Target

By TipRanks

327.13% upside

12 Months Forecast

Average 4.997 EUR  327.13%

High 5 EUR

Low 5 EUR

Based on 1 Wall Street analysts offering 12 month price targets forAB Science SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

1.426 / 1.448Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About AB Science SA

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
help-icon Live chat